Roundtable participants from Citeline and Dr. Reddy's.

Last updated: Nov 7, 2025


This roundtable highlights India’s biopharma sector and explores key strategies to boost and support its biopharma ecosystem.


Overview

New technologies are revolutionizing drug discovery worldwide. However, e ciently exploiting these technological advances to develop new drugs and get them to patients can be extremely challenging. Many stakeholders play signi cant roles in this complex process, including academic researchers, industry, government agencies, industry, and more.

“Mainstreaming some of the new age therapies and emerging technologies will require the whole ecosystem to go along – integrated data platforms, the funding environment, streamlining regulatory pathways, the patents system, addressing payer dynamics, etc.” – Anju Ghangurde, Citeline

As India strives to become a larger player in the biopharma sector moving from cost-based to value and innovation-based growth, experts are focusing on addressing a variety of issues like collaborative research, funding mechanisms, the regulatory environment, and the clinical trial infrastructure. To focus greater attention and resources, and to generate increased momentum in support of the sector, industry and government leaders have developed long-term targets to promote and accelerate biopharma innovation


Download

Related resources

How Companies Tackle Diversity in Clinical Trials_resource-card-thumbnail
NOV 06, 2023
Article
Clinical

Diversity in Clinical Trials: How Companies Are Tackling the Issue

When it comes to clinical trial diversity, life sciences companies are taking steps to move the needle in the right direction.

a group of pills and capsules
JUL 01, 2023
Article
Commercial

Floodgates Open for US Humira Biosimilars; Key TB Drug Can Move in India

Generics Bulletin previews the most notable and anticipated events for July 2023

Innovation in Europe_search-thumbnail
FEB 01, 2023
White paper
Clinical

The State of Innovation in Europe

Europe’s drug innovative pipeline has reached a plateau, and is underexposed to high-growth areas such as oncology, cell and gene therapy.